Max Rosett - 02 Oct 2023 Form 3 Insider Report for Immunome Inc. (IMNM)

Role
SVP Operations
Signature
/s/ Sandra Stoneman, Attorney-in-Fact
Issuer symbol
IMNM
Transactions as of
02 Oct 2023
Net transactions value
$0
Form type
3
Filing time
12 Oct 2023, 18:36:23 UTC
Next filing
31 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IMNM Common Stock 19,856 02 Oct 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IMNM Stock Option (Right to Buy) 02 Oct 2023 Common Stock 39,713 $1.35 Direct F2
holding IMNM Stock Option (Right to Buy) 02 Oct 2023 Common Stock 133,848 $1.06 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Mr. Rosett was appointed as SVP Operations of the Issuer effective immediately after the Effective Time (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by and among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.). In connection with the Closing (as defined in the Merger Agreement) and prior to Mr. Rosett being appointed an executive officer of the Issuer, Mr. Rosett exchanged (i) his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer and (ii) his shares of common stock of Morphimmune for shares of the Issuer.
F2 25% of the shares vested on March 24, 2023, and the remaining shares shall vest in 36 monthly installments thereafter.

Remarks:

See Attached Exhibit 24